Sue Fleck

©MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects

S. McCormack, R. Shattock, P. Hayes, 2020 .

The Safety and Immunogenicity of GTU®MultiHIV DNA Vaccine Delivered by Transcutaneous and Intramuscular Injection With or Without Electroporation in HIV-1 Positive Subjects on Suppressive ART

S. McCormack, R. Shattock, P. Hayes, 2019, Front. Immunol..

Optimizing the immunogenicity of HIV prime-boost DNA-MVA-rgp140/GLA vaccines in a phase II randomized factorial trial design

S. McCormack, M. Hoelscher, M. Robb, 2018, PloS one.

Neurocognitive Function in HIV-Infected Patients: Comparison of Two Methods to Define Impairment

A. Winston, J. Ainsworth, J. Day, 2014, PloS one.

Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine

S. McCormack, S. Kent, P. McKay, 2018, Human gene therapy.

Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)

J. Ainsworth, M. Gompels, A. Arenas-Pinto, 2024, EClinicalMedicine.